Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Platelet Lysate for Persistent Corneal Epithelial Defects
NCT02979912Phase 2Completed
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous human platelet lysate in persistent corneal epithelial defect (PED). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 months. Started Feb 2017; status: completed.
02
Drugs
autologous human platelet lysate
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT02979912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979912.